After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...